The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Open accessAbstract
IMPORTANCE: Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. OBJECTIVE: To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colorectal Cancer (FIRE-3) trial. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3 trials were classified as having left-sided or right-sided mCRC, defined, respectively, as patients whose tumors originated in the splenic flexure, descending colon, sigmoid colon, or rectum vs appendix, cecum, ascending colon, hepatic flexure, or transverse colon. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were assessed according to tumor location and treatment arm. RESULTS: In the RAS wt populations of the CRYSTAL and FIRE-3 trials, patients with left-sided tumors (n = 142 and n = 157, respectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n = 33 and n = 38, respectively). Among CRYSTAL and FIRE-3 study patients with RAS wt left-sided tumors, FOLFIRI plus cetuximab significantly improved OS relative to the respective comparators (FOLFIRI and FOLFIRI plus bevacizumab); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy benefits were observed upon the addition of cetuximab to FOLFIRI in CRYSTAL, and comparable outcomes were observed between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab arms of FIRE-3. A significant interaction was observed between primary tumor location and treatment for OS (CRYSTAL: hazard ratio [HR], 1.95; 95% CI, 1.09-3.48 and FIRE-3: HR, 0.40; 95% CI, 0.23-0.70) within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status. CONCLUSIONS AND RELEVANCE: In the RAS wt populations of CRYSTAL and FIRE-3, patients with left-sided tumors had a markedly better prognosis than those with right-sided tumors. First-line FOLFIRI plus cetuximab clearly benefitted patients with left-sided tumors (vs FOLFIRI or FOLFIRI plus bevacizumab, respectively), whereas patients with right-sided tumors derived limited benefit from standard treatments. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: CRYSTAL, NCT00154102, and FIRE-3, NCT00433927.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bevacizumab is effective regardless of RAS gene status”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citationVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationPowell, A. E., Wang, Y., Li, Y., Poulin, E. J., Means, A. L., Washington, M. K., Higginbotham, J. N., Juchheim, A., Prasad, N., Levy, S. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.042 · Cited by 694
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Self-citationPrimary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477
Self-citationBrule, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R. P. W., Tebbutt, N. C., Underhill, C. R., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 335
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 710
Tabernero, J. M., Taı̈eb, J., Prager, G. W., Ciardiello, F., Fakih, M., Leger, C., Fougeray, R., Amellal, N., & Cutsem, E. V. (2021) · Future Oncology · doi:10.2217/fon-2020-1238 · Cited by 50
Self-citationQin, Q., Yang, L., Sun, Y., Ying, J., Song, Y., Zhang, W., Wang, J., & Zhou, A. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.02.004 · Cited by 47
Park, S., Hwang, C. Y., Cho, S., Lee, D., Gong, J., Lee, S., Nam, S., & Cho, K. (2019) · FEBS Journal · doi:10.1111/febs.14773 · Cited by 47
Wang, G., He, Y., Sun, Y., Wang, W., Qian, X., Yu, X., & Pan, Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02213-9 · Cited by 45
Synthesis of novel 1,3,4-oxadiazole derivatives as potential antimicrobial agents.
Chawla, R., Arora, A., Parameswaran, M., Chan, P., Sharma, D., Michael, S., & Ravi, T. K. (2010) · PubMed · Cited by 44
Zheng, C., Jiang, F., Lin, H., & Li, S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02083-1 · Cited by 43
Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer
Malakorn, S., Ouchi, A., Hu, C., Sandhu, L., Dasari, A. N., You, Y. N., Kopetz, S., Ellis, L. M., & Chang, G. J. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.08.007 · Cited by 43
Ulivi, P., Scarpi, E., Chiadini, E., Marisi, G., Valgiusti, M., Capelli, L., Gardini, A. C., Monti, M., Ruscelli, S., Frassineti, G. L., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061240 · Cited by 42
Tan, T., Mouradov, D., Lee, M., Gard, G., Hirokawa, Y., Li, S., Lin, C., Li, F., Luo, H., Wu, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101335 · Cited by 47
Oct4 Gene Expression in Primary Colorectal Cancer Promotes Liver Metastasis
Fujino, S., & Miyoshi, N. (2019) · Stem Cells International · doi:10.1155/2019/7896524 · Cited by 41
Erve, I. V. ’., Medina, J. E., Leal, A., Papp, E., Phallen, J. A., Adleff, V., Chiao, E. J., Arun, A. S., Bolhuis, K., Simmons, J. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2538 · Cited by 47
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 43
Liver transplantation in metastatic colorectal cancer: are we ready for it?
Ros, J., Salvà, F., Dopazo, C., López-Valbuena, D., Gonzalez, N. S., Baraibar, I., Charco, R., Tabernero, J. M., & Élez, E. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02213-1 · Cited by 40
Self-citationWang, K., Xu, D., Yan, X., Poston, G. J., & Xing, B. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.02.210 · Cited by 39
Peeters, M., Price, T. J., Taı̈eb, J., Geißler, M., Rivera, F., Canon, J.-L. R., Pentheroudakis, G. E., Koukakis, R., Burdon, P., & Siena, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0165-z · Cited by 39
Liu, W., Wang, H., Wang, K., & Xing, B. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.04.017 · Cited by 38
Song, Y., Wang, L., Ran, W., Li, G., Xiao, Y., Wang, X., Zhang, L., & Xing, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00096 · Cited by 37
Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers
Chabab, G., Boissière‐Michot, F., Mollévi, C., Ramos, J., Lopez‐Crapez, E., Colombo, P., Jacot, W., Bonnefoy, N., & Lafont, V. (2020) · Cells · doi:10.3390/cells9061537 · Cited by 42
Comparison of Right-side and Left-side Colon Cancers Following Laparoscopic Radical Lymphadenectomy
Kwak, H. D., Ju, J. K., Lee, S. Y., Kim, C. H., Kim, Y. J., & Kim, H. R. (2019) · Journal of Investigative Surgery · doi:10.1080/08941939.2019.1608334 · Cited by 36
Hamid, M. A., Pammer, L. M., Oberparleiter, S., Günther, M., Amann, A., Gruber, R., Mair, A., Nocera, F. I., Ormanns, S., Zimmer, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00892-y · Cited by 41
Right Versus Left Colon Cancer: Resectable and Metastatic Disease
Ghidini, M., Petrelli, F., & Tomasello, G. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0544-y · Cited by 37
Shida, D., Tanabe, T., Boku, N., Takashima, A., Yoshida, T., Tsukamoto, S., & Kanemitsu, Y. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07209-x · Cited by 36
Tumor-suppressive function and mechanism of HOXB13 in right-sided colon cancer
Xie, B., Bai, B., Xu, Y., Liu, Y., Lv, Y., Gao, X., Wu, F., Fang, Z., Lou, Y., Pan, H., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0086-1 · Cited by 36
Hubbard, J. M., Tőke, E. R., Moretto, R., Graham, R. P., Youssoufian, H., Lőrincz, O., Molnár, L., Csiszovszki, Z., Mitchell, J. L., Wessling, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0112 · Cited by 36
MSI colorectal cancer, all you need to know
Flecchia, C., Zaanan, A., Lahlou, W., Basile, D., Broudin, C., Gallois, C., Pilla, L., Karoui, M., Manceau, G., & Taı̈eb, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101983 · Cited by 40
Practice-changing updates in the adjuvant and metastatic setting
Puccini, A., & Lenz, H. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.185 · Cited by 36
Self-citationMuta, Y., Linares, J. F., Martínez-Ordóñez, A., Durán, Á., Cid-Diaz, T., Kinoshita, H., Zhang, X., Han, Q., Nakanishi, Y., Nakanishi, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43690-5 · Cited by 35
Ciepiela, I., Szczepaniak, M., Ciepiela, P., Hińcza, K., Kopczyński, J., Macek, P., Kubicka, K., Chrapek, M., Tyka, M., Góźdź, S. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55139-w · Cited by 42
Riedl, J. M., Posch, F., Moik, F., Bezan, A., Szkandera, J., Smolle, M. A., Kasparek, A.-K., Pichler, M., Stöger, H., Stotz, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21647 · Cited by 35
Maitland, M. L., Wilkerson, J., Karovic, S., Zhao, B., Flynn, J. R., Zhou, M., Hilden, P. D., Ahmed, F. S., Dercle, L., Moskowitz, C. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1493 · Cited by 36
Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review
DeStefanis, R. A., Kratz, J. D., Emmerich, P. B., & Deming, D. A. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00430-6 · Cited by 34
Kanno, H., Miyoshi, H., Yoshida, N., Sudo, T., Nakashima, K., Takeuchi, M., Nomura, Y., Seto, M., Hisaka, T., Tanaka, H., et al. (2020) · Cancer Science · doi:10.1111/cas.14495 · Cited by 34
Battaglin, F., Puccini, A., Djaballah, S. A., & Lenz, H. (2019) · Cancer Management and Research · doi:10.2147/cmar.s186042 · Cited by 36
Self-citationMatsumoto, A., Shimada, Y., Nakano, M., Oyanagi, H., Tajima, Y., Nakano, M., Kameyama, H., Hirose, Y., Ichikawa, H., Nagahashi, M., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7561 · Cited by 34
Arai, H., Xiao, Y., Loupakis, F., Kawanishi, N. K., Wang, J., Battaglin, F., Soni, S., Zhang, W., Mancao, C., Salhia, B., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001714 · Cited by 34
Self-citationCurrent concepts of anti-EGFR targeting in metastatic colorectal cancer
Doleschal, B., Petzer, A., & Rumpold, H. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1048166 · Cited by 36
Jang, J. Y., Kim, D., & Kim, N. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098457 · Cited by 32
Wensink, G. E., Bond, M. J. G., Küçükköse, E., May, A. M., Vink, G. R., Koopman, M., Kranenburg, O., & Roodhart, J. M. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102174 · Cited by 35
Update on systemic therapy for colorectal cancer: biologics take sides
Gbolahan, O. B., & O’Neil, B. H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.01.12 · Cited by 33
Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 34
Liu, X., Xu, X., Wu, Z., Shan, Q., Wang, Z., Wu, Z., Ding, X., Huang, W., & Wang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961350 · Cited by 35
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
Kim, S. Y., & Kim, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000634 · Cited by 33
Grassadonia, A., Marino, P. D., Ficorella, C., Cortellini, A., Cannita, K., Parisi, A., Gamucci, T., Zoratto, F., Vici, P., Barba, M., et al. (2019) · Journal of Cancer · doi:10.7150/jca.34550 · Cited by 31
Randon, G., Maddalena, G., Germani, M. M., Pircher, C. C., Manca, P., Bergamo, F., Giordano, M., Sposetti, C., Montagna, A., Vetere, G., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00037 · Cited by 34
Wang, Z.-X., Wu, H.-X., He, M.-M., Wang, Y.-N., Luo, H.-Y., Ding, P.-R., Xie, D., Chen, G., Li, Y.-H., Wang, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7279 · Cited by 29
Sastre, J., de la Orden, V., Martínez, A., Bando, I., Balbı́n, M., Bellosillo, B., Palanca, S., Peligros, M. I., Mediero-Valeros, B., Llovet, P., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.014 · Cited by 31
You, X.-H., Jiang, Y., Fang, Z., Sun, F., Li, Y., Wang, W., Xia, Z., Wang, X.-Z., & Ying, H. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000605 · Cited by 30
Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies
Zhang, X., Zhang, W., & Cao, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629390 · Cited by 30
Narayanan, S., Gabriel, E. M., Attwood, K. M., Boland, P. M., & Nurkin, S. J. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.001 · Cited by 30
Bouchahda, M., Saffroy, R., Karaboué, A., Hamelin, J., Innominato, P. F., Saliba, F., Lévi, F., Bosselut, N., & Lemoine, A. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00400 · Cited by 30
Erve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 30
Uhlig, J., Cecchini, M., Sheth, A. H., Stein, S., Lacy, J., & Kim, H. S. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7619 · Cited by 29
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
Garajová, I., Ferracin, M., Porcellini, E., Palloni, A., Abbati, F., Biasco, G., & Brandi, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071547 · Cited by 28
Berger, M. D., Stintzing, S., Heinemann, V., Cao, S., Yang, D., Sunakawa, Y., Matsusaka, S., Ning, Y., Okazaki, S., Miyamoto, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1663 · Cited by 29
Self-citationSantos, C. G., Azuara, D., Viéitez, J. M., Páez, D., Falcó, E., Élez, E., López, C., Valladares, M., Robles-Díaz, L., Alfonso, P. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz082 · Cited by 28
Distinct Prognosis of High Versus Mid/Low Rectal Cancer: a Propensity Score–Matched Cohort Study
Cheng, L.-J., Chen, J., Chen, S., Wei, Z.-W., Yu, L., Han, S.-P., He, Y., Wu, Z., & Chen, C. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-04072-1 · Cited by 28
Kienle, D., Dietrich, D., Ribi, K., WICKI, A. N., Quagliata, L., Winterhalder, R. C., Koeberle, D., Horber, D., Bastian, S., Kueng, M., et al. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.11.011 · Cited by 28
First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm
Cremolini, C., Antoniotti, C., Moretto, R., Masi, G., & Falcone, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.219 · Cited by 28
Shimada, Y., Kameyama, H., Nagahashi, M., Ichikawa, H., Muneoka, Y., Yagi, R., Tajima, Y., Okamura, T., Nakano, M., Sakata, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20510 · Cited by 27
Shimada, Y., Tajima, Y., Nagahashi, M., Ichikawa, H., Oyanagi, H., Okuda, S., Takabe, K., & Wakai, T. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.020 · Cited by 27
Williams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X.-M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0120 · Cited by 26
Post-pulmonary metastasectomy prognosis after curative resection for colorectal cancer
Kim, J. Y., Park, I. J., Kim, H. R., Kim, D. K., Lee, J. L., Yoon, Y. S., Kim, C. W., Lim, S., Lee, J. B., Yu, C. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16616 · Cited by 27
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 27
Buisman, F. E., Galjart, B., Buettner, S., Koerkamp, B. G., Grünhagen, D. J., & Verhoef, C. K. (2019) · HPB · doi:10.1016/j.hpb.2019.10.003 · Cited by 26
Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study
Ge, Y., Lei, S., Cai, B., Gao, X., Wang, G., Wang, L., & Wang, Z. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03434-8 · Cited by 26
dos Santos, E. S., Rodrigues‐Fernandes, C. I., Speight, P. M., Khurram, S. A., Alsanie, I., Normando, A. G. C., Ribeiro, A. C. P., Brandão, T. B., Kowalski, L. P., Guerra, E. N. S., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103352 · Cited by 26
Kim, S. R., Song, N., Yothers, G., Gavin, P. G., Allegra, C. J., Paik, S., & Pogue–Geile, K. L. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.448 · Cited by 26
Goel, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s162967 · Cited by 26
Wang, Z., Wang, X., Zhang, Z., Wang, X., Chen, M., Lu, L., Zhu, W., Zhang, J., Jia, H., & Chen, J. (2019) · Journal of Cancer · doi:10.7150/jca.29294 · Cited by 26
Cao, D., Xu, H., Xu, X., & Ge, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19022 · Cited by 25
Ciliberto, D., Staropoli, N., Caglioti, F., Chiellino, S., Ierardi, A., Ingargiola, R., Botta, C., Arbitrio, M., Correale, P., Tassone, P., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.003 · Cited by 26
Marques, M. C., Ribeiro, H. S. C., da Costa, W. L., de Jesus, V. H. F., de Macêdo, M. P., Diniz, A. L., de Godoy, A. L., de Farias, I. C., Aguiar, S., Riechelmann, R. P., et al. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25048 · Cited by 25
Roberto, M., Marchetti, P., Arrivi, G., Pietro, F. R. D., Cascinu, S., Gelsomino, F., Caputo, F., Cerma, K., Ghidini, M., Ratti, M., et al. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03589-9 · Cited by 42
Stahler, A., Stintzing, S., Modest, D. P., Ricard, I., Gießen-Jung, C., Kapaun, C., Ivanova, B., Kaiser, F., von Weikersthal, L. F., Moosmann, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2748 · Cited by 26
Self-citationOligometastatic Disease in Colorectal Cancer - How to Proceed
Aigner, F., Pratschke, J., & Schmelzle, M. (2017) · Visceral Medicine · doi:10.1159/000454688 · Cited by 25
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan, H. T., Emilescu, R. A., Iaciu, C. I., Orlov-Slavu, C. M., Olaru, M., Popa, A. M., Jinga, M., Niţipir, C., Schreiner, O. D., & Ciobanu, R. C. (2024) · Cancers · doi:10.3390/cancers16233928 · Cited by 27
ten Hoorn, S., Sommeijer, D. W., Elliott, F., Fisher, D. J., de Back, T. R., Trinh, A. C., Koens, L., Maughan, T., Seligmann, J. F., Seymour, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01477-9 · Cited by 25
Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer
Ahmed, S., Pahwa, P., Le, D., Chalchal, H. I., Kanthan, S. C., Iqbal, N., & Fields, A. L. A. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.11.001 · Cited by 24
Kamran, S. C., Clark, J. W., Zheng, H., Borger, D. R., Blaszkowsky, L. S., Allen, J. N., Kwak, E. L., Wo, J. Y.-L., Parikh, A. R., Nipp, R. D., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1558 · Cited by 24
Nie, C., Lv, H., Chen, B., Xu, W., Wang, J., Liu, Y., Wang, S., Zhao, J., He, Y., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.917353 · Cited by 22
Yang, G., Yu, X., Weisenberger, D. J., Lü, T., & Liang, G. (2023) · Cancers · doi:10.3390/cancers15112934 · Cited by 25
Chiu, J. W. Y., Krzyzanowska, M. K., Serra, S., Knox, J. J., Dhani, N. C., MacKay, H. J., Hedley, D. W., Moore, M. J., Liu, G., Burkes, R. L., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.010 · Cited by 23
Bai, B., Shan, L., Xie, B., Huang, X., Mao, W., Wang, X., Wang, D., & Zhu, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.7709 · Cited by 23
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 22
Yang, L.-P., Wang, Z., Zhang, R., Zhou, N., Wang, A., Liang, W., Wang, Z., Luo, H., Wang, F., Liu, J., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02815-4 · Cited by 23
Hegewisch‐Becker, S., Nöpel‐Dünnebacke, S., Hinke, A., Graeven, U., Reinacher‐Schick, A., Hertel, J., Lerchenmuller, C. A., Killing, B., Depenbusch, R., Al‐Batran, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.015 · Cited by 22
Targeting EGFR in Esophagogastric Cancer
Maron, S. B., Xu, J. R., & Janjigian, Y. Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.553876 · Cited by 22
APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
Thota, R., Yang, M., Pflieger, L. T., Schell, M. J., Rajan, M., Davis, T. B., Wang, H., Presson, A. P., Pledger, W. J., & Yeatman, T. J. (2021) · Cancers · doi:10.3390/cancers13215394 · Cited by 22
Sunakawa, Y., Satake, H., Usher, J. L., Jaimes, Y. S., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100512 · Cited by 22
Self-citationWilliams, C. J. M., Elliott, F., Sapanara, N. L., Aghaei, F., Zhang, L., Murányi, A., Yan, D., Bai, I., Zhao, Z., Shires, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0859 · Cited by 22
Updates on the Management of Colorectal Cancer in Older Adults
O'Donnell, C., Hubbard, J. M., & Jin, Z. (2024) · Cancers · doi:10.3390/cancers16101820 · Cited by 28
Demurtas, L., Puzzoni, M., Giampieri, R., Ziranu, P., Pusceddu, V., Mandolesi, A., Cremolini, C., Masi, G., Gelsomino, F., Antoniotti, C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.178 · Cited by 22
Cremolini, C., Benelli, M., Fontana, E., Pagani, F., Rossini, D., Fucà, G., Busico, A., Conca, E., Donato, S. D., Loupakis, F., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000489 · Cited by 22
Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review
Bañobre, J. R., Kandimalla, R., & Goel, A. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00260 · Cited by 25
Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management
Lieu, C. H., Corcoran, R. B., & Overman, M. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240839 · Cited by 22
Recent advances in understanding colorectal cancer
Stintzing, S. (2018) · F1000Research · doi:10.12688/f1000research.14604.1 · Cited by 21
Self-citationPrognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients
Ottaiano, A., Scala, S., Normanno, N., Botti, G., Tatangelo, F., Mauro, A. D., Capozzi, M., Facchini, S., Tafuto, S., & Nasti, G. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000828 · Cited by 20
Khan, A. R., Ditta, A., Mehmood, M. S., Mao-sheng, Z., & Natalia, M. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-14739-z · Cited by 21
Metadata
- Authors
- Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Ludwig-Maximilians-Universität München (DE)
- University of Campania "Luigi Vanvitelli" (IT)
- Universitat Autònoma de Barcelona (ES)
- Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium
- Merck KGaA, Darmstadt (Germany) (DE)
- University of Southern California (US)
- Corresponding author
- Tejpar, Sabine
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 194
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC7505121
- OpenAlex
- W2531319683
- Cited by
- 709
- References
- 24
- Citations by year
- 2026: 19 · 2025: 35 · 2024: 64 · 2023: 48 · 2022: 70 · 2021: 89 · 2020: 85 · 2019: 97 · 2018: 102 · 2017: 96
- FWCI
- 53.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- National Cancer Institute (P30CA014089)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, RAS wild-type, primary tumor site, cetuximab, FOLFIRI, bevacizumab, first-line therapy, progression-free survival, overall survival, objective response rate, predictive biomarkers, CRYSTAL trial, FIRE-3 trial, EGFR inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
